Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710349 | 0.91 | HIF1A (0.38) | GPR35HIF1AMEN1KMT2AHPGD | |
| SCHEMBL6712224 | 0.89 | HIF1A (0.34) | HIF1ALRRK2 | |
| SCHEMBL6709888 | 0.88 | HIF1A (0.47) | HIF1A | |
| SCHEMBL6708933 | 0.87 | LRRK2 (0.38) | HIF1ALRRK2 | |
| SCHEMBL6711660 | 0.87 | HIF1A (0.43) | HIF1ACXCR1CXCR2ALDH1A1LRRK2 | |
| SCHEMBL6711746 | 0.87 | HIF1A (0.41) | HIF1AMAPTALDH1A1LRRK2 | |
| SCHEMBL6709172 | 0.86 | HIF1A (0.42) | GPR35HIF1AMEN1KMT2AHPGD | |
| SCHEMBL6710262 | 0.86 | HIF1A (0.42) | HIF1AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6710477 | 0.85 | TNIK (0.38) | HIF1AMAPTLRRK2 | |
| SCHEMBL6709855 | 0.85 | F2 (0.43) | HIF1AMEN1KMT2ARAB9ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GPR35 2928/4885HIF1A 296/4885MEN1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.